相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Risk of Cardiovascular Disease Events in Patients With Type 2 Diabetes Prescribed the Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Exenatide Twice Daily or Other Glucose-Lowering Therapies A retrospective analysis of the LifeLink database
Jennie H. Best et al.
DIABETES CARE (2011)
Effects of Exenatide on Systolic Blood Pressure in Subjects With Type 2 Diabetes
Ted Okerson et al.
AMERICAN JOURNAL OF HYPERTENSION (2010)
One-year treatment with exenatide vs. Insulin Glargine: Effects on postprandial glycemia, lipid profiles, and oxidative stress
Mathijs C. Bunck et al.
ATHEROSCLEROSIS (2010)
The exenatide analogue AC3174 attenuates hypertension, insulin resistance, and renal dysfunction in Dahl salt-sensitive rats
Que Liu et al.
CARDIOVASCULAR DIABETOLOGY (2010)
Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure
Que Liu et al.
CARDIOVASCULAR DIABETOLOGY (2010)
Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study
Anne Gill et al.
CARDIOVASCULAR DIABETOLOGY (2010)
One-year metabolic outcomes in patients with type 2 diabetes treated with exenatide in routine practice
M. Buysschaert et al.
DIABETES & METABOLISM (2010)
Exenatide Affects Circulating Cardiovascular Risk Biomarkers Independently of Changes in Body Composition
Mathijs C. Bunck et al.
DIABETES CARE (2010)
Incretin-Based Therapies for the Treatment of Type 2 Diabetes: Evaluation of the Risks and Benefits
Daniel J. Drucker et al.
DIABETES CARE (2010)
Epidemiologic Relationships Between A1C and All-Cause Mortality During a Median 3.4-Year Follow-up of Glycemic Treatment in the ACCORD Trial
Matthew C. Riddle et al.
DIABETES CARE (2010)
Benefit-Risk Assessment of Exenatide in the Therapy of Type 2 Diabetes Mellitus
Baptist Gallwitz
DRUG SAFETY (2010)
Resting heart rate in patients with stable coronary artery disease and diabetes: a report from the Euro Heart Survey on Diabetes and the Heart
Matteo Anselmino et al.
EUROPEAN HEART JOURNAL (2010)
Risk of Acute Myocardial Infarction, Stroke, Heart Failure, and Death in Elderly Medicare Patients Treated With Rosiglitazone or Pioglitazone
David J. Graham et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Rosiglitazone and the Case for Safety Over Certainty
David N. Juurlink
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Setting the RECORD Straight
Steven E. Nissen
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Weighing Risks and Benefits of Liraglutide -- The FDA's Review of a New Antidiabetic Therapy.
Mary Parks et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Revisiting the Rosiglitazone Story - Lessons Learned
Clifford J. Rosen
NEW ENGLAND JOURNAL OF MEDICINE (2010)
The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study
Denise E. Bonds et al.
BMJ-BRITISH MEDICAL JOURNAL (2010)
Efficacy and safety of exenatide in patients of Asian descent with type 2 diabetes inadequately controlled with metformin or metformin and a sulphonylurea
Yan Gao et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2009)
Risk of cardiovascular disease and mortality in overweight and obese patients with type 2 diabetes: an observational study in 13,087 patients
K. Eeg-Olofsson et al.
DIABETOLOGIA (2009)
Exenatide Exhibits Dose-Dependent Effects on Glycemic Control over 12 Weeks in Japanese Patients with Suboptimally Controlled Type 2 Diabetes
Takashi Kadowaki et al.
ENDOCRINE JOURNAL (2009)
Diabetes medications and body weight
Joanna Mitri et al.
EXPERT OPINION ON DRUG SAFETY (2009)
Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
John B. Buse et al.
LANCET (2009)
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial
Philip D. Home et al.
LANCET (2009)
Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes
William Duckworth et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, parallel-group study
Thomas J. Moretto et al.
CLINICAL THERAPEUTICS (2008)
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
Anushka Patel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Effects of intensive glucose lowering in type 2 diabetes
Hertzel C. Gerstein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Effect of a multifactorial intervention on mortality in type 2 diabetes
Peter Gaede et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
10-year follow-up of intensive glucose control in type 2 diabetes
Rury R. Holman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Management of Hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy - Update regarding thiazolidinediones: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes
David M. Nathan et al.
DIABETES CARE (2008)
Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: A multinational, randomized, open-label, two-period, crossover noninferiority trial
Anthony H. Barnett et al.
CLINICAL THERAPEUTICS (2007)
Exploring the substitution of exenatide for insulin in patients with type 2 diabetes treated with insulin in combination with oral antidiabetes agents
Stephen N. Davis et al.
DIABETES CARE (2007)
Fixed vs random effects meta-analysis in rare event studies:: The Rosiglitazone link with myocardial infarction and cardiac death
Jonathan J. Shuster et al.
STATISTICS IN MEDICINE (2007)
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes
Steven E. Nissen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study
M. A. Nauck et al.
DIABETOLOGIA (2007)
Primary prevention of cardiovascular diseases in people with diabetes mellitus - A scientific statement from the American Heart Association and the American Diabetes Association
John B. Buse et al.
DIABETES CARE (2007)
QT(c) interval and resting heart rate as long-term predictors of mortality in type 1 and type 2 diabetes mellitus: a 23-year follow-up
C. Stettler et al.
DIABETOLOGIA (2007)
Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure
George G. Sokos et al.
JOURNAL OF CARDIAC FAILURE (2006)
Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes
L. Blonde et al.
DIABETES OBESITY & METABOLISM (2006)
Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus
R. E. Ratner et al.
DIABETES OBESITY & METABOLISM (2006)
Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts
Tingcun Zhao et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
DM Nathan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea
DM Kendall et al.
DIABETES CARE (2005)
Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes
RA DeFronzo et al.
DIABETES CARE (2005)
Testing the equality of two Poisson means using the rate ratio
HKT Ng et al.
STATISTICS IN MEDICINE (2005)
Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury
AK Bose et al.
DIABETES (2005)
Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion
LA Nikolaidis et al.
CIRCULATION (2004)
The UGDP controversy - thirty-four years of contentious ambiguity laid to rest
TB Schwartz et al.
PERSPECTIVES IN BIOLOGY AND MEDICINE (2004)
Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy
LA Nikolaidis et al.
CIRCULATION (2004)
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes
JB Buse et al.
DIABETES CARE (2004)
The heart protection study: Expanding the boundaries for high-risk coronary disease prevention
JA Farmer et al.
AMERICAN JOURNAL OF CARDIOLOGY (2003)
Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study
IM Stratton et al.
BMJ-BRITISH MEDICAL JOURNAL (2000)
分享论文
